Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts ...

Why do we focus on the bad news stories about cuts and crises in classical music ? Musicians are doing incredible things to engage, support and sustain us; we should tell those stories too When did ...

Mr. Shinners is a pianist and harpsichordist and hosts the podcast “W.T.F. Bach.” Classical music has been in a crisis for decades. New generations don’t seem to care about it. The institutions that ...

This year’s 2026 Preview consists of all the entertainment — from movies to books to art shows — that Vulture writers and editors are excited to consume in the New Year. Below, our classical-music ...

Performances in N.Y.C. Advertisement Supported by Listen to recordings by Maria Dueñas and Daniil Trifonov, works by Thomas Adès and Tania León, and more. London Philharmonic Orchestra; Thomas Adès, ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Lots of people are excited about the idea of using plants to help us draw down some of the excess carbon dioxide we’ve been pumping into the atmosphere. It would be nice to think that we could ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...